Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

AIDS

Volumn 27, Issue 6, 2013, Pages 939-950

  Cohen, Calvin J ^a   Molina, Jean Michel ^b   Cassetti, Isabel ^c   Chetchotisakd, Ploenchan ^d   Lazzarin, Adriano ^e   Orkin, Chloe ^f   Rhame, Frank ^g   Stellbrink, Hans Jürgen ^h   Li, Taisheng ⁱ   Crauwels, Herta ^j   Rimsky, Laurence ^j   Vanveggel, Simon ^j   Williams, Peter ^j   Boven, Katia ^k  

^a Boston Community Research Initiative of New England   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Helios Salud ^*  (Argentina)

^d KHON KAEN UNIVERSITY   (Thailand)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f BARTS HEALTH NHS TRUST   (United Kingdom)

^g ABBOTT NORTHWESTERN HOSPITAL   (United States)

^h Infektionsmedizinisches Centrum Hamburg   (Germany)

ⁱ PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^j JANSSEN RESEARCH FOUNDATION   (Belgium)

^k JANSSEN RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

Efavirenz; HIV 1; Rilpivirine; Treatment naive

Indexed keywords

EFAVIRENZ; PLACEBO; RILPIVIRINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPHYXIA; ATYPICAL MYCOBACTERIOSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAINTNESS; FEMALE; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYDROCORTISONE BLOOD LEVEL; HYPERTRANSAMINASEMIA; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCEMIA; NIGHTMARE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUICIDE ATTEMPT; TREATMENT RESPONSE; TUBERCULOUS OSTEOMYELITIS; UNCONSCIOUSNESS; VIRUS LOAD; VITAL SIGN;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DRUG TOXICITY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NITRILES; PYRIMIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84876406278     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835cee6e     Document Type: Article

References (38)

1. DHHS Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents, March 2012 http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. [Accessed 20 December 2012].
2. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection 2012 Recommendations of the International AIDS Society: USA Panel. JAMA 2012; 308:387-402.
3. EACS European Guidelines for treatment of HIV infected adults in Europe. Version 6.1, November 2012. Available at: http://www. europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelines-v6. 1-English-Nov2012.pdf. [Accessed 7 December 2012].
4. Pérez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1, 033 HIV-infected patients. HIV Clin Trials 2002; 3:279-286.
5. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253-1263.
6. van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004; 1:e19.
7. Hill A, Sawyer W, Gazzard B. Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin Trials 2009; 10:1-12.
8. Davidson I, Beardsell H, Smith B, Mandalia S, Bower M, Gazzard B, et al. The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study. Antiviral Res 2010; 86:227-229.
9. Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005; 21:743-752.
10. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003; 34:407-414.
11. Zheng J, Scourfield A, Waters L, Cevik M, Mandalia S, Nelson M. Discontinuation of tenofovir, emtricitabine and efavirenz as a single tablet regime in HIV-1 infected individuals naive to antiretroviral therapy [abstract H2-783]. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17-20 September 2011; Chicago, IL, USA.
12. EDURANT® (rilpivirine) tablets. Full prescribing information. Janssen, Inc., August 2012. http://www.edurant-info.com/sites/default/files/ EDURANT-PI.pdf. [Accessed 7 December 2012].
13. EDURANT®25mg film-coated tablets. Summary of Product Characteristics. Janssen-Cilag International NV, August 2012. http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/002264/WC500118874.pdf. [Accessed 7 December 2012].
14. COMPLERA® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) tablets. Full prescribing information. Gilead Sciences, August 2012. http://www.gilead.com/pdf/complera-pi.pdf. [Accessed 7 December 2012].
15. EVIPLERA® 200 mg/25 mg/245mg film-coated tablets. Summary of product characteristics. Gilead Sciences Ltd, 2012. http://www.medicines.org.uk/emc/ medicine/25518/SPC/. [Accessed 7 December 2012].
16. Cohen C, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naïve, HIV-1-infected patients: pooled results from the phase 3 double-blind, randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr 2012; 60:33-42.
17. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, noninferiority trial. Lancet 2011; 378:229-237.
18. Molina J-M, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378:238-246.
19. Rimsky L, Vingerhoets J, Van Eygen V, Eron J, Clotet B, Hoogstoel A, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir ImmuneDefic Syndr 2012; 59:39-46.
20. Vingerhoets J, Rimsky L, Van Eygen V, Nijs S, Vanveggel S, Boven K, et al. Screening and baseline mutations in the TMC278 phase III trials ECHO and THRIVE: prevalence and impact on virological response. Antivir Ther 2011; 16 (Suppl 1):A51.
21. Flandre P. Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials. PLoS ONE 2011; 6:e22871.
22. FDA Guidance for Industry. Antiretroviral drugs using plasma HIV RNA measurements: clinical considerations for accelerated and traditional approval, prepared by the Division of Antiviral Drug Products. Office of Drug Evaluation IV in the Centre for Drug Evaluation and Research (CDER), Appendix B, October 2002. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070968.pdf [Accessed 7 December 2012].
23. Qaqish R, van Wyk J, King MS. A comparison of the FDA TLOVR and FDA snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens [abstract P58]. In: Tenth International Congress on Drug Therapy in HIV Infection (HIV10); 7-11 November 2010; Glasgow, UK.
24. Brochot A, De La Rosa G, Vis P, Corbett C, Vanveggel S, Cohen CJ, et al. Generalized Additive Modeling of virologic response to the nonnucleoside reverse transcriptase inhibitors rilpivirine and efavirenz in treatment-naïve HIV-infected patients: pooled data from ECHO and THRIVE [abstract PS12/7]. In: 13th European AIDS Conference; 12-15 October 2011; Belgrade, Serbia.
25. Johnson VA, Brun-Vézinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009; 17:138-145.
26. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004; 292:191- 201.
27. Pozniak Al, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naïve patients: virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43:535-540.
28. Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010; 55:39-48.
29. Sierra-Madero J, Di Perri G, Wood R, Frank I, Saag M, Craig CI, et al. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials 2010; 11:125-132.
30. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154:445-456.
31. Azijn H, Tirry I, Vingerhoets J, de Béthune MP, Kraus G, Boven K, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010; 54:718-727.
32. Kulkarni R, Babaoglu K, Lansdon EB, Rimsky L, Van Eygen V, Picchio G, et al. The HIV-1 reverse transcriptase M184I mutation enhances the E128K-associated resistance to rilpivirine and decreases viral fitness. J Acquir Immune Defic Syndr 2012; 59:47-54.
33. Xu HT, Asahchop EL, Oliveira M, Quashie PK, Quan Y, Brenner BG, et al. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol 2011; 85:11300-11308.
34. Hu Z, Kuritzkes DR. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol 2011; 85:11309-11314.
35. Margot NA, Waters JM, Miller MD. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrob Agents Chemother 2006; 50:4087- 4095.
36. Ruxrungtham K, Pedro RJ, Latiff GH, Conradie F, Domingo P, Lupo S, et al. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitornai ̈ve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med 2008; 9:883- 896.
37. INTELENCE® (etravirine) tablets. Full prescribing information. Janssen Pharmaceuticals, Inc., August 2012. http://www.intelence-info.com/sites/ default/files/pdf/INTELENCE-Booklet-Package-Insert-hcp.pdf. [Accessed 7 December 2012].
38. INTELENCE® (etravirine): Summary of product characteristics. Janssen-Cilag Ltd., August 2012http://www.medicines.org.uk/EMC/medicine/21185/ SPC/Intelence+100+mg+tablets/. [Accessed 7 December 2012].